Tue, Jul 22, 2014, 8:55 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Stemline Therapeutics, Inc. Message Board

  • sudhanva_n sudhanva_n Jun 19, 2013 7:38 PM Flag

    Ladenburg starts Stemline Therapeutics at buy

    Ladenburg Thalmann has initiated coverage of Stemline Therapeutics (NASDAQ:STML) with a “buy” rating and $36 price target, saying that at current prices, it views Stemline as an “attractive investment opportunity with significant upside potential.”
    Stemline is in the process of developing two anti-cancer therapeutic products, SL-401 and SL-701, targeting tumor bulk and cancer stem cells (CSCs), which could potentially enable Stemline to generate greater than $500-million in revenue annually,” writes analyst Matthew Kaplan.

    SL-401 is being developed for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML) and other hematologic cancers, while SL-701 is under development for adult glioblastoma multiforme and pediatric brainstem and non-brainstem glioma.

    “We believe Stemline’s current valuation offers significant upside potential, particularly if the products are efficacious in the other indications Stemline plans to pursue, beyond BPDCN and AML,” Mr. Kaplan said.

    “We believe the breadth of the clinical programs Stemline has planned will attract the attention of possible partners, and will continue to de-risk the product portfolio as more data are generated,” he added.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
STML
11.19+0.29(+2.66%)Jul 22 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Puma Biotechnology, Inc.
NYSETue, Jul 22, 2014 4:01 PM EDT
Microsoft Corporation
NasdaqGSTue, Jul 22, 2014 4:00 PM EDT